about
Cancer stem cell targeted therapy: progress amid controversies.Aptamer for imaging and therapeutic targeting of brain tumor glioblastomaNucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical SensingCan nanomedicines kill cancer stem cells?CD133, Selectively Targeting the Root of CancerDevelopment of Cell-SELEX Technology and Its Application in Cancer Diagnosis and TherapyDirect validation of aptamers as powerful tools to image solid tumorSelection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein BiomarkersAptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells.Efficient HIV-1 inhibition by a 16 nt-long RNA aptamer designed by combining in vitro selection and in silico optimisation strategies.Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicineAptamers: versatile probes for flow cytometry.Molecular Recognition of Human Liver Cancer Cells Using DNA Aptamers Generated via Cell-SELEX.EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial CancerSuperior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid TumorsAn integrated microfluidic system for screening of phage-displayed peptides specific to colon cancer cells and colon cancer stem cells.RNA as a stable polymer to build controllable and defined nanostructures for material and biomedical applicationsAptamers as theranostic agents: modifications, serum stability and functionalisationAptamer identification of brain tumor-initiating cells.Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells.Oligonucleotide aptamers: new tools for targeted cancer therapy.Novel methodologies in analysis of small molecule biomarkers and living cells.Selection and characterization of DNA aptamer against glucagon receptor by cell-SELEX.Nucleic acid aptamers in cancer research, diagnosis and therapy.Nanocarrier-mediated drugs targeting cancer stem cells: an emerging delivery approach.Cancer stem cells and personalized cancer nanomedicine.Microfluidics in the selection of affinity reagents for the detection of cancer: paving a way towards future diagnostics.The promotion of salinomycin delivery to hepatocellular carcinoma cells through EGFR and CD133 aptamers conjugation by PLGA nanoparticles.Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells.Gefitinib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers target lung cancer stem cells.Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.Effects of a Phosphoinositide-3-Kinase Inhibitor on Anaplastic Thyroid Cancer Stem CellsTransforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery.Selection and targeting of EpCAM protein by ssDNA aptamer.Aptamer-Based Therapeutic Approaches to Target Cancer Stem Cells.Development of docetaxel liposome surface modified with CD133 aptamers for lung cancer targeting.Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications.Development of Cell-Specific Aptamers: Recent Advances and Insight into the Selection Procedures.Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects.Dual-modified cationic liposomes loaded with paclitaxel and survivin siRNA for targeted imaging and therapy of cancer stem cells in brain glioma
P2860
Q26779931-0E411174-22CF-486E-A184-C2807F320D07Q26799218-99B44A50-4DC0-48CD-9B89-8BA655AD4CA8Q26825644-51A57EBC-B586-4647-8C48-29D5AD2171C6Q27022017-D9E25E92-208E-46B7-A53B-72268737F7DCQ28066353-DEB35A8D-257D-4097-9896-05DD862A8F99Q28080168-AB1FAC30-FD29-4D07-A007-07F1DC36CFE4Q33632641-E3F9B265-5297-4819-AFF5-D35C4FDA8892Q33832781-9467F6C5-44C7-470C-8920-8095A3FAAAE8Q33919094-84CD9288-F4E2-47EB-A687-E87F5AD908B7Q34112867-FFC8CFAC-3081-484B-AC74-363418B5FD0FQ34698624-2CB44846-DF0B-4C34-A479-736FE5E98146Q34803826-E13D6C0A-148D-411B-99A0-A1D4167A4578Q35621766-E63183FC-6FAA-4FFA-86CF-0019776513C5Q35691811-B909659C-6B5F-48EF-AEB4-88529420F343Q35868868-36084710-BEDD-4055-8B31-0B60DBCEB64BQ36171577-5D07B1AE-5F0C-4F78-B6A4-7428B3AC7049Q36449335-23CADD2B-D5F9-435D-8CD9-166BAFA316F0Q37383122-48A74E1B-5325-4F8C-8513-13D1A3B351B1Q37601425-63DA765C-4944-454E-9F87-0A47F359E2C6Q37607750-04A46DA8-257E-437B-B546-D356998CFDB3Q38237132-37CFDD9E-FBBE-4162-A05B-0700DA18187EQ38239586-05F7B51C-AC14-4838-B715-595CC7919FA8Q38287579-9B462C40-D7D3-4B85-899B-E2F792FEAC08Q38308357-959305A2-193D-4B10-B472-9457A6A01585Q38324456-4594C544-D598-4B5F-AACE-2C40B5F5360AQ38702970-856F30E4-0FAE-4CD3-AE76-2A7786B58542Q38844919-FC897A9C-CD90-43F9-808F-3FB45C9E86D7Q38857110-F336E594-A884-4D6D-AD34-96FC46C58DE2Q38890185-C31A8EBC-A227-4654-93D6-0A3907C05128Q41571715-4797EF8A-CFE2-452D-9D56-0226AE18E38EQ42317503-CE1E5AD3-F740-4BF2-B2D8-92A56F59B1BBQ47107349-F5ED1867-0D9F-4072-BC5C-C8498CDA9E17Q47108689-3D9D8D64-2BC7-4EF0-BF89-E1DD4D8D772BQ47134382-DB7E3631-6FD8-4FDB-BEFF-AC5067F62358Q47168257-A5496932-1E36-4F70-B224-82D076ED2000Q47627194-EE7E8FD9-50AC-4A07-BC22-602DE02E2117Q47942947-64F67F45-0305-478F-B9E9-0EB3F99B5A01Q49545795-A8124644-8253-4AEF-AC3A-1DBDD0C16CB6Q55036897-C5E4E3F1-EE11-4C90-BB82-4F3FD81F02BBQ57024281-8C3A9D73-9638-446C-B06E-A3E66DD2DA73
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
RNA aptamers targeting cancer stem cell marker CD133.
@en
RNA aptamers targeting cancer stem cell marker CD133.
@nl
type
label
RNA aptamers targeting cancer stem cell marker CD133.
@en
RNA aptamers targeting cancer stem cell marker CD133.
@nl
prefLabel
RNA aptamers targeting cancer stem cell marker CD133.
@en
RNA aptamers targeting cancer stem cell marker CD133.
@nl
P2093
P50
P1433
P1476
RNA aptamers targeting cancer stem cell marker CD133
@en
P2093
Dongxi Xiang
Liang Qiao
Lianhong Li
Sarah Shigdar
Shu-Feng Zhou
P356
10.1016/J.CANLET.2012.11.032
P407
P577
2012-11-27T00:00:00Z